Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal type A on Mammaprint, after knowing that the patient had a poor response to neoadjuvant endocrine therapy?

Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal A subtype on Mammaprint, with poor response to neoadjuvant ET?

• Yes, would add adjuvant chemotherapy on basis of poor response to endocrine therapy
• No, would continue with ET adjuvantly and add CDK4/6i if eligible by stage/extent of disease
• No, would continue with ET adjuvantly and add CDK4/6i regardless of stage/extent of disease
• Would retest Mammaprint on new sample and base decisions on updated molecular analysis (eg: adding chemotherapy if luminal B, continuing endocrine therapy if confirmed Luminal A)
• Other